Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma.
[INTRODUCTION] Anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease is a rare but fatal adverse event following immune checkpoint inhibitor treatment for cancers
APA
Saito A, Ishihara H, et al. (2026). Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma.. IJU case reports, 9(2), e70148. https://doi.org/10.1002/iju5.70148
MLA
Saito A, et al.. "Anti-Melanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease, Induced by Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma.." IJU case reports, vol. 9, no. 2, 2026, pp. e70148.
PMID
41660501
Abstract
[INTRODUCTION] Anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease is a rare but fatal adverse event following immune checkpoint inhibitor treatment for cancers. However, such cases have not been previously reported in patients with urothelial carcinoma.
[CASE PRESENTATION] A 79-year-old Japanese woman with advanced unresectable bladder cancer was treated with first-line enfortumab vedotin plus pembrolizumab. During the second treatment cycle, interstitial lung disease developed, and the patient immediately received steroid pulse therapy. As interstitial lung disease rapidly progressed after the initiation of steroid pulse therapy, immunosuppressive treatment with cyclophosphamide and tacrolimus was added. However, interstitial lung disease did not improve, and the patient died on day 54 after initiating treatment. Detailed antibody examination revealed positive anti-melanoma differentiation-associated gene 5 antibodies.
[CONCLUSION] We report the first case of anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease induced by enfortumab vedotin plus pembrolizumab in a patient with advanced urothelial carcinoma.
[CASE PRESENTATION] A 79-year-old Japanese woman with advanced unresectable bladder cancer was treated with first-line enfortumab vedotin plus pembrolizumab. During the second treatment cycle, interstitial lung disease developed, and the patient immediately received steroid pulse therapy. As interstitial lung disease rapidly progressed after the initiation of steroid pulse therapy, immunosuppressive treatment with cyclophosphamide and tacrolimus was added. However, interstitial lung disease did not improve, and the patient died on day 54 after initiating treatment. Detailed antibody examination revealed positive anti-melanoma differentiation-associated gene 5 antibodies.
[CONCLUSION] We report the first case of anti-melanoma differentiation-associated gene 5 antibody-positive interstitial lung disease induced by enfortumab vedotin plus pembrolizumab in a patient with advanced urothelial carcinoma.
같은 제1저자의 인용 많은 논문 (5)
- Cytomegalovirus-encoded immediate early 1 protein perturbs neural progenitor proliferation via interfering with host PML-DISC1 interaction.
- Triple-hit TdT-positive high-grade B-cell lymphoma mimicking B-lymphoblastic lymphoma and exhibiting immunophenotypic change at relapse.
- Expression of Claudin18.2 in metastatic lesions in peritoneum of gastric cancer.
- Analysis of clinicopathological features and oncological outcomes of ulcerative colitis-associated colorectal cancer based on macroscopic classification.
- [A Case of Pial Arteriovenous Fistulae Associated with Hereditary Hemorrhagic Telangiectasia].